RNA therapeutics companies develop medicines that use RNA molecules to alter protein production, silence disease-associated genes or deliver therapeutic instructions to cells. These approaches support the treatment of genetic disorders, cancer, infectious disease and other conditions.
This category includes companies working on:
Browse 48 UK RNA therapeutics companies below.
Genomics platform developing RNA therapies for chronic liver disease
Ochre Bio is a biotechnology company developing RNA therapeutics for chronic liver disease using a platform built on large-scale human liver datasets. The platform integrates gene…
National innovation centre accelerating drug discovery
Medicines Discovery Catapult (MDC) is an independent, not-for-profit national innovation centre that supports UK medicines discovery organisations across the full drug discovery…
MicroRNA therapeutics for tendon and musculoskeletal disease
Causeway Therapeutics is a clinical-stage biotechnology company developing first-in-class microRNA therapies for musculoskeletal and age-related conditions. Its lead asset TenoMiR…
Contract synthesis of custom and modified oligonucleotides
ATDBio is a UK-based contract oligonucleotide synthesis company specialising in chemically modified DNA and RNA oligonucleotides for therapeutic and diagnostic applications. Its…
RNAi brain shuttle platform for neurodegenerative disease drug delivery
Aerska is a biotechnology company developing RNA interference medicines to treat, delay and prevent diseases of the brain. The company's antibody oligonucleotide conjugate…
Clinical-stage precision oncology developing first-in-class TACC3 inhibitor therapeutics
Coiled Therapeutics is a UK-listed, clinical-stage oncology company developing precision cancer therapeutics against structurally complex, previously undruggable targets. Its lead…
AI-powered RNAi drug discovery company developing hepatic medicines
Tangram Therapeutics is a biotechnology company combining artificial intelligence and RNA interference to discover and develop novel medicines. Its proprietary chemistry platform…
Oncolytic virus immunotherapies engineered to destroy solid tumours
Bioarchitech is a preclinical-stage biotechnology company developing oncolytic virus-based immunotherapies for the treatment of common solid tumours. The company engineers…
siRNA gene therapies targeting root causes of ALS and frontotemporal dementia
Crucible Therapeutics Limited is a preclinical-stage biotechnology company developing siRNA-based gene therapies for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia…
Engineered iPSC-derived exosomes for tissue-targeted drug delivery
Excellio Labs is a biotech developing engineered exosome platforms for targeted drug delivery. The technology exploits the inherent tissue-specificity of iPSC-derived…
Antisense oligonucleotide gene therapies for rare childhood leukodystrophies
SynaptixBio is a rare disease biotech company developing gene therapies for severe leukodystrophies and childhood neurodegenerative diseases, using antisense oligonucleotide…
In vivo immune cell reprogramming for autoimmune and inflammatory disease
Flip Therapeutics is a biotechnology company developing in vivo immune cell engineering therapies for chronic autoimmune and inflammatory diseases, including multiple sclerosis,…